Extraintestinal Manifestations of Inflammatory Bowel Disease

At every IBD evaluation, document new inflammatory joint symptoms, eye pain or redness, oral lesions, tender nodules or ulceration, urinary symptoms or renal dysfunction, and cholestatic symptoms. IBD-associated extraintestinal manifestations involve joints, skin, eyes, kidneys, and the hepatobiliary system; more than one manifestation may coexist. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH

Escalate immediately for a painful red eye, photophobia, reduced vision, or suspected uveitis; ocular inflammation is included among recognized IBD complications, and uveitis may progress independently of bowel activity. accessdata fda+1accessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCHfdaCrohn's Disease: Developing Drugs for Treatment A red eye that is limited to episcleritis is more likely to track colitis activity, but the distinction should not delay ophthalmologic assessment when visual symptoms or significant pain are present. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH

Treat rapidly progressive painful cutaneous ulceration as possible pyoderma gangrenosum rather than assuming cellulitis or a routine IBD flare. Pyoderma gangrenosum may occur and progress independently of bowel inflammation; coordinate dermatology evaluation while reassessing intestinal inflammatory control. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH

For new dyspnea, edema, weight loss, fever, abdominal mass, fistula drainage, or perianal pain, determine whether the driver is intestinal inflammation, IBD complication, or systemic consequence. Anemia and hypoalbuminemia can cause dyspnea and peripheral edema, while Crohn disease can be complicated by obstruction, abscess, sinus tracts, and fistulas. accessdata fda+1accessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCHBMJCrohn disease - Symptoms, diagnosis and treatment | BMJ Best Practice US

When an extraintestinal manifestation is new or worsening, first determine whether there is concurrent intestinal activity or an alternative trigger. In ulcerative colitis, diagnosis requires endoscopy with biopsy and negative stool culture; obtain stool culture in every flare because relapse may be associated with pathogens. BMJ+1BMJUlcerative colitis - Symptoms, diagnosis and treatment | BMJ Best PracticeBMJUlcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice US This prevents escalation of immunosuppression for infectious diarrhea mislabeled as active colitis.

For suspected or newly characterized Crohn disease, integrate compatible clinical features with endoscopy, histology, and cross-sectional or other appropriate imaging. Crohn disease may involve any GI segment and is transmural, creating a separate pathway for strictures, perforation, abscesses, sinuses, fistulas, and perianal disease. fda+1fdaPediatric Inflammatory Bowel Disease: Developing Drugs ...BMJCrohn disease - Symptoms, diagnosis and treatment | BMJ Best Practice US

Use objective clinical findings to define accompanying disease burden. In the Crohn Disease Activity Index, listed complications include arthritis or arthralgia, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, anal fistula or abscess, other fistula, and fever above 37.8°C; these findings should be recorded rather than collapsed into a nonspecific report of 'systemic symptoms.' fdafdaCrohn's Disease: Developing Drugs for Treatment

In pediatric Crohn disease, fever at least 38.5°C for 3 days in the preceding week, definite arthritis, uveitis, erythema nodosum, or pyoderma gangrenosum count as extraintestinal manifestations in the Pediatric Crohn Disease Activity Index. Low albumin, elevated erythrocyte sedimentation rate, weight loss, and perianal findings add objective evidence of systemic and intestinal burden. BMJBMJManagement of Crohn's disease

Arthritis is among the most commonly recognized extraintestinal manifestations of IBD, and peripheral arthritis, aphthous stomatitis, erythema nodosum, pyoderma gangrenosum, psoriasis, and uveitis are described in pediatric IBD. accessdata fda+1accessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCHfdaPediatric Inflammatory Bowel Disease: Developing Drugs ... For every patient with joint complaints, record the distribution, functional limitation, objective swelling, and coexistence of skin, eye, oral, or bowel activity because these features determine whether the presentation fits an inflammatory multisystem pattern.

When erythema nodosum or episcleritis appears during worsening ulcerative colitis symptoms, prioritize confirmation and control of colitis activity because these manifestations often occur concurrently with flares. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH Conversely, persistent arthritis, pyoderma gangrenosum, or uveitis despite apparently controlled bowel symptoms should trigger organ-specific assessment rather than repeated empiric escalation based only on gastrointestinal symptoms. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH

Aphthous stomatitis, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, arthritis or arthralgia, and fever are explicit complication variables in the Crohn Disease Activity Index. fdafdaCrohn's Disease: Developing Drugs for Treatment Their presence should be captured longitudinally, because a change in these variables may represent clinically meaningful disease burden even when stool frequency alone is unchanged.

In children with Crohn disease and coexistent inflammatory arthritis, methotrexate is identified as particularly suitable as a first-line maintenance option; the cited pediatric regimen is 15 mg/m² subcutaneously once weekly, maximum 25 mg, with folate supplementation. BMJBMJManagement of Crohn's disease This is pediatric Crohn disease guidance and should not be extrapolated as a universal adult regimen or as acute therapy for any individual extraintestinal manifestation.

Do not infer ocular severity from bowel activity. Episcleritis may occur with ulcerative colitis flares, whereas uveitis may occur and progress independently of bowel inflammation. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH The decision point is symptom severity: pain, photophobia, or visual change warrants urgent ophthalmologic evaluation rather than observation for response to gastrointestinal treatment.

Primary sclerosing cholangitis is a recognized hepatobiliary manifestation of IBD and may progress independently of intestinal inflammation. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH New cholestatic laboratory abnormalities or hepatobiliary symptoms should therefore prompt a liver-focused assessment rather than be interpreted as evidence of inadequate control of colitis alone.

Renal manifestations of IBD include nephrolithiasis, amyloidosis, tubulointerstitial nephritis, and glomerulonephritis. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH In a patient with flank pain, hematuria, proteinuria, rising creatinine, or edema, separate stone disease from intrinsic renal disease and from edema attributable to hypoalbuminemia; renal findings should not be dismissed as nonspecific extraintestinal symptoms. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH

IBD with primary sclerosing cholangitis carries important colorectal cancer implications. In a national cohort, IBD overall was associated with increased colorectal cancer risk versus controls (hazard ratio 1.83, 95% CI 1.72-1.96), and risk was highest initially among patients with PSC before decreasing over time. Wolters KluwerWolters KluwerImpact of Inflammatory Bowel Disease and Primary... : Clinical Gastroenterology & Hepatology Use PSC status as a major risk modifier when planning longitudinal colorectal neoplasia surveillance.

When a manifestation tracks intestinal activity, treat the active bowel disease after objective reassessment and exclusion of infectious relapse, particularly in ulcerative colitis where stool culture should be obtained in every flare. BMJ+1BMJUlcerative colitis - Symptoms, diagnosis and treatment | BMJ Best PracticeBMJUlcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice US Erythema nodosum and episcleritis are examples of manifestations that commonly coincide with ulcerative colitis flares. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH

When a manifestation is independent of bowel activity, avoid a bowel-only management plan. Uveitis, pyoderma gangrenosum, and primary sclerosing cholangitis may progress despite improvement in luminal inflammation, requiring concurrent ophthalmologic, dermatologic, or hepatobiliary management. accessdata fdaaccessdata fdaCENTER FOR DRUG EVALUATION AND RESEARCH In Crohn disease, treatment planning also must account for stricturing, penetrating, and perianal complications, which may require interventions beyond medical treatment of luminal disease. fda+1fdaPediatric Inflammatory Bowel Disease: Developing Drugs ...BMJCrohn disease - Symptoms, diagnosis and treatment | BMJ Best Practice US

Use standardized documentation to monitor both intestinal and extraintestinal response. Crohn Disease Activity Index complication fields capture arthritis or arthralgia, iritis or uveitis, erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, fistulas or abscesses, and fever above 37.8°C. fdafdaCrohn's Disease: Developing Drugs for Treatment In pediatric assessment, document fever at least 38.5°C for 3 days, definite arthritis, uveitis, erythema nodosum, and pyoderma gangrenosum, alongside albumin, erythrocyte sedimentation rate, growth, weight, and perianal findings. BMJBMJManagement of Crohn's disease

Refer early for coordinated specialty care when IBD is diagnosed or when advanced therapies and serious adverse-effect monitoring are required. Crohn disease management requires specialist input from diagnosis because regimens require frequent response assessment and expertise in managing potentially serious adverse events. BMJBMJCrohn disease - Symptoms, diagnosis and treatment | BMJ Best Practice US This need is amplified when an extraintestinal manifestation is organ-threatening, refractory, or discordant with intestinal activity.